Genetic Study of Pseudoexfoliation Syndrome
About the Research Project
Program
Award Type
Standard
Award Amount
$69,985
Active Dates
April 01, 2003 - September 30, 2005
Grant ID
G2003027
Summary
Pseudoexfoliation glaucoma is considered the most common identifiable glaucoma in the world. It affects millions of individuals throughout the world and leads to elevated intraocular pressure (IOP), which is associated with the death of optic nerve cells. Pseudoexfoliation material is found throughout many eye and body tissues. Dr. Challa is working to identify the genes involved in pseudoexfoliation syndrome by comparing gene products in people with pseudoexfoliation to the genetics of those without it. He will also compare the gene products between people with pseudoexfoliation who have glaucoma with those who have pseudoexfoliation but no glaucoma. By learning these differences, he hopes to shed light on a possible cause of this disorder, and why some people who have the disorder develop glaucoma while others don’t. With this information, it may be possible to develop new tests and treatments for glaucoma.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
National Glaucoma Research
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego